Influence of variants of Fcg receptor IIA on the European league against rheumatism responses to anti-tumour necrosis factor alpha therapy in psoriatic arthritis
© Ramirez et al; licensee BioMed Central Ltd. 2010
Published: 25 November 2010
The efficacy of biological therapies currently used in psoriatic arthritis depends not only on their blocking effect on the targeted molecule but also on the affinity of genetically defined variants of the Fc-gamma receptors for the constant portion (Fc fragment of IgG1).
To determine whether polymorphisms in Fc-gamma receptor IIA influence clinical efficacy in patients with psoriatic arthritis treated with tumor necrosis factor alpha inhibitors.
Patients and methods
The study population comprised 110 patients (52.7% males and 47.3% females) with psoriatic arthritis refractory to 15 mg or more of methotrexate/week. Infliximab (33.6%), etanercept (50.9%) or adalimumab (15.5%) were initiated, and patients were evaluated after 12 and 24 weeks using the EULAR response criteria. Genotyping of FCGR IIA-H131R polymorphism was performed by allele-specific PCR and PCR sequence-based typing. The chi-square test was used to compare response rates across Fc-gamma receptor IIA genotype.
12 weeks EULAR Response FCGRIIA
24 weeks EULAR response FCGRIIA
These results suggest that FCGR IIA-H131R polymorphism has low influence in the clinical efficacy of anti-TNF therapies in patients with psoriatic arthritis. Although different to previously reported results in rheumatoid arthritis, these results can be explained because of the better and more prolonged response to anti-TNF therapy in psoriatic arthritis than in rheumatoid arthritis. In addition, in this study we analyzed patients with three different anti-TNF-alpha therapies.